NewsRoom Articles - Page 149 of 154 - PsychedelicNewsWire (PNW)

WednesdayFeb 14, 2018 4:04 pm

Medical Cannabis Payment Solutions (REFG) CEO Confident About Utah Cannabis Bill Success

Proposed legislation would be more moderate than a current legalization initiative but allow more concessions than a more conservative bill submitted this season Jeremy Roberts is confident the yet undrafted bill will be ready for consistent debate before the end of the current legislative session on March 8 Cannabis is illegal in Utah, with only one exception: non-psychoactive medical CBD oil extract is allowed for patients suffering from severe epilepsy A medical cannabis bill that would advocate a more moderate approach and would “bridge the gap” between two very different legalization initiatives currently underway, has every chance to be successful,…

WednesdayFeb 14, 2018 3:10 pm

Marijuana Company of America, Inc. (MCOA) Executing a Strategy Aligned with Future Forces

WHO recommends that CBD not be a controlled substance Operations at various points in the cannabis and industrial hemp industries Launch of new products for convenience stores Two major trends are fostering the success Marijuana Company of America, Inc. (OTC: MCOA) is having. With 29 states and the District of Columbia now permitting the use of cannabis for either medicinal or recreational purposes and public stigma surrounding cannabinoids fast fading, the cannabis and cannabidiol (CBD) industry is moving toward a maturity that will make it an economic sector to be reckoned with. At the same time, an increasingly health-conscious American…

MondayFeb 12, 2018 11:53 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expanding Best-in-Class Product Line

Lexaria has developed an oral digestion technology that may translate into lower dosages and shorter treatment regimens Company is expanding its edible product offerings through a licensing agreement with a Canadian cannabis chocolate manufacturer Lexaria continues to develop products for demonstration, testing and sales Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed DehydraTECH™, an oral digestion technology believed to improve the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs), vitamins and cannabinoids by as much as five to ten times the normal rate. The time of onset is also reduced, and effects are felt within 15 to 20 minutes…

TuesdayFeb 06, 2018 1:35 pm

Recent Report on PotNetwork Holding Inc. (POTN) Share Price Target Highlights Encouraging Data

Heightened share price target for PotNetwork Holding Inc. set at $1.25 Previous market estimates, exceeded by over 70 percent, show positive month-to-month sales for PotNetwork Holdings Inc. SeeThruEquity report highlights the greatly lowered legal and physiological risk from hemp-derived CBD A recent comprehensive report by SeeThruEquity highlighting PotNetwork Holding Inc. (OTC: POTN) and its subsidiary, Diamond CBD, projected a heightened share price target set at $1.25. The increase was attributed to the company’s strong monthly sales data and 3Q17 filings (http://cnw.fm/A2krk). Per the report, these indicated “continued profitability as the company invests in growth.” In a prior news release, Dr.…

FridayFeb 02, 2018 12:28 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer

Lexaria enters agreement with Cannfections to develop an innovative range of cannabis-infused chocolates and gummies incorporating its proprietary technology, DehydraTECH™ Cannfection’s formulation and manufacturing expertise can be offered to other Lexaria licensee partners The agreement is expected to generate new cannabis-based edible products for domestic and international markets On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://cnw.fm/Hef3A). Cannfections is a new company, established by one of…

ThursdayJan 25, 2018 3:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids Uplisted to OTCQX® Best Market Licensing model generates profit margins in excess of 90 percent A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://cnw.fm/Eay21). While warning against the risk of nicotine addiction posed by vaping, the report claimed “that the devices are safer than traditional smoking products and may help smokers quit, citing conclusive proof that switching can reduce smokers’ exposure to deadly…

TuesdayJan 23, 2018 3:47 pm

Grey Cloak Tech’s (GRCK) Recent Eqova Acquisition Positions the Company for Growth on Booming CBD Market

Hemp-derived cannabidiol (CBD) sales projected to surpass $1 billion in five years Grey Cloak Tech has acquired Eqova Life Sciences, an established producer of a range of clinical-grade CBD products This acquisition strengthens Grey Cloak’s position in this market sector and is likely to accelerate its growth On the back of several forecasts of explosive growth in the cannabidiol (CBD) market, Grey Cloak Tech, Inc. (OTCQB: GRCK) has made a strategic decision to focus its efforts in this sector. The Hemp Business Journal reports projected growth of 700 percent by 2020, to reach annual sales of $2.1 billion, according to…

TuesdayJan 23, 2018 1:07 pm

Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Portfolio Growing

Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs Active pharmaceutical ingredient market expected to exceed $239 billion by 2025 19 patent applications filed in U.S. and internationally encompassing 44 countries Lab tests in 2018 include topical CBD skin cream, nicotine in edible formats Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million…

TuesdayJan 16, 2018 2:03 pm

Earth Science Tech, Inc. (ETST) is “One to Watch”

Biotech company focused on production of cutting-edge industrial hemp, cannabis/cannabidiol (CBD) products R&D efforts include nutraceuticals, pharmaceuticals, bioceuticals, phytoceuticals and cosmeceuticals catering to health, wellness and alternative medicine markets International provisional patent application targets CBD’s powerful medicinal benefits Integration of CBD molecule with generic drug molecules opens new medical frontier U.S. consumer market for cannabinoid-based pharmaceuticals estimated at $50 billion by 2029 Medical diagnostic device MSN-2 slated for clinical tests to validate detection of various STDs Global market for diagnostic testing of STDs expected to reach $108.5 billion by 2019 Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology…

WednesdayDec 27, 2017 3:49 pm

World Health Organization Officially Rules CBD Should Not be a Scheduled Drug

The World Health Organization (WHO) announced that “the cannabis compound CBD (Cannabidiol) should not be internationally scheduled as a controlled substance” (www.WHO.int) WHO has issued preliminary findings indicating that cannabidiol (CBD) shows “no indications of abuse or dependence potential” and “a good safety profile” MCOA is committed to the development of high quality CBD-based products The World Health Organization (“WHO”) officially recommended on December 14, 2017, that the chemical compound cannabidiol (CBD) no longer be internationally scheduled as a controlled substance. WHO has issued a preliminary report that found CBD to be non-addictive and generally safe. The CBD pre-review report…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000